(Q43938501)

28 November 2017

title

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study (English)

1 reference

28 November 2017

4

1 reference

28 November 2017

Rafael Marcos-Gragera

7

1 reference

28 November 2017

Gemma Osca-Gelis

10

0 references

Pamela Minicozzi

Pamela Minicozzi

2

0 references

Roberta De Angelis

Roberta De Angelis

12

0 references

Milena Sant

Milena Sant

1

0 references

Hermann Brenner

Hermann Brenner

5

0 references

Bernd Holleczek

6

Bernd Holleczek

1 reference

28 November 2017

0 references

Morgane Mounier

3

1 reference

28 November 2017

Marc Maynadié

8

1 reference

28 November 2017

Alain Monnereau

9

1 reference

28 November 2017

Otto Visser

11

1 reference

28 November 2017

EUROCARE-5 Working Group

13

1 reference

28 November 2017

publication date

13 July 2014

1 reference

Lancet Oncology Commission

28 November 2017

published in

1 reference

28 November 2017

volume

15

1 reference

28 November 2017

issue

9

1 reference

28 November 2017

page(s)

931-942

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Regression models for relative survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Standard cancer patient population for age standardising survival ratios

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

Up-to-Date Long-Term Survival Curves of Patients With Cancer by Period Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970282-7

7 January 2021

10.1016/S1470-2045(14)70282-7

Identifiers

DOI

1 reference

28 November 2017

1 reference